Leap Therapeutics

LEAP THERAPEUTICS INC

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

LPTX

Biotech

News

Health Care

Movers

Trading Ideas

General

Leap Therapeutics&#39; Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

iPad's Impact On Apple

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

AAPL

DDOG

MRNA

TCBX

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Leap Therapeutics&#39; Phase 2 data shows sirexatamab improves ORR in colorectal cancer. Gastric cancer studies end due to lack of PFS benefit.

Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes

Leap Therapeutics Inc

Earnings

Press Releases

Leap Therapeutics Reports First Quarter 2024 Financial Results

Leap Therapeutics Reports Second Quarter 2024 Financial Results

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment

CSDX

OSRH

THTX

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

CEL-SCI

Elevation Oncology

Equillium

GlycoMimetics

HCW Biologics

Imunon

IN8bio

Kairos Pharma

Lisata Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

MetaVia

BiomX

Palatin Techs

Spruce Biosciences

Synlogic

Unity Biotechnology

Rodman & Renshaw

Baird

Mizuho

Raymond James

Comments

Leap Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga